Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Biotecnologia

Mr. Jonathan D. Siegal

Principal Accounting Officer, Vice President & Corporate Controller

Mr. Mike  Gilligan

Senior Vice President of Sales

Mr. Sean C. Flynn

Chief Legal Officer

Mr. Patrick J. Fowler

Senior Vice President of Corporate Development & Strategy

Mr. Michael  Halpin

Chief Operating Officer

Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B.

Chief Medical Officer

Mr. Patrick  Helfrich

Vice President of Marketing & Commercial Strategy

Mr. Eric  Burns

Vice President of Finance & Investor Relations

Mr. Dominick C. Colangelo Esq.

Chief Executive Officer, President & Director

Mr. Joseph Anthony Mara Jr.

Chief Financial Officer & Treasurer

Nome	Capitalizzazione di mercato
Sorrento Therapeutics, Inc.	0M
Maravai LifeSciences Holdings, Inc.	0M
Comera Life Sciences Holdings, Inc.	0M
Gubra A/S	0M
CytoTools AG	0M
Hofseth BioCare ASA	0M
Shanghai Haohai Biological Technology Co., Ltd.	0M
Purple Biotech Ltd.	0M

Vericel Corporation

Vericel Corporation Elenco dei concorrenti

Principali concorrenti